Archive
All News
Every briefing, headline, and filing we've published, newest first.
PipelineBriefing
Three months post-Avadel acquisition, Alkermes’ Lumryz met all endpoints in the phase 3 Revitalyz study for id…
The WeekDrug Channels ↗
By Bryce Platt, PharmD The onslaught of pharmacy-related news doesn’t end. It may even be increasing in volume…
PipelineSTAT News ↗
Doctors have linked a boy's tumor to a gene therapy, but say the rare risks need to be weighed against the pro…
DealsEndpoints News ↗
Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill …
PipelinePharmaceutical Technology ↗
An indirect comparison highlights the potential of BridgeBio's Attruby to best Pfizer’s tafamidis in frontline…
MoneyFiercePharma ↗
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another ind…
PipelineFierceBiotech ↗
Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, e…
DealsBriefing
Bristol Myers Squibb will pay $600M upfront in a $15.2B collaboration with Hengrui, aiming to leverage China’s…
PolicyDrug Channels ↗
Join Dr. Adam J. Fein, president of Drug Channels Institute (DCI) and the editor of Drug Channels, for his lat…
PipelinePharmaceutical Technology ↗
Partner Therapeutics has received FDA approval for Bizengri to treat adults with advanced, unresectable or met…
NegotiationsEndpoints News ↗
UnitedHealth Group’s Optum Rx on Monday unveiled a new approach to prescription drug benefits that it said off…
DealsBioPharma Dive ↗
The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and c…
MoneyFierceBiotech ↗
Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million…
MoneyFiercePharma ↗
Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to…
MoneyBriefing
Vancouver’s Optimi Health launched a 2.5M-share IPO just as U.S. policy momentum boosts psychedelics research,…
MoneyEndpoints News ↗
CSL's stock hit its lowest price since early 2017 on Monday after it lowered its full-year revenue guidance by…
PipelinePharmaceutical Technology ↗
BMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic …
PolicySTAT News ↗
Doctors and insurers are battling to reshape the controversial No Surprises Act arbitration process, which has…
PipelineFiercePharma ↗
After a surprise rejection in January, the FDA has agreed to reconsider a T-cell therapy based on the same sin…
DealsFierceBiotech ↗
For people living with exocrine pancreatic insufficiency due to cystic fibrosis, the only treatment option is …
PolicyBriefing
With FDA review of deramiocel approaching, Capricor alleges NS Pharma halted launch prep and failed to fix a p…
PolicySTAT News ↗
The CDC is playing an unusually small, and quiet, role in responding to the hantavirus outbreak.…
PolicyFiercePharma ↗
During the weeklong stay by the Supreme Court to temporarily restore online access to the abortion pill mifepr…
PipelineFierceBiotech ↗
Entrada Therapeutics’ Duchenne muscular dystrophy data have fallen well short of expectations, crashing the bi…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.